drugset / Trial / NCT00650195

Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

NCT00650195

Phase 1 Completed 56 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions.

Timeline

Start
2004-02
Primary completion
2004-02
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Metolazone Small molecule 10 mg Oral

Indications

No indication recorded.